Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.750
+0.160 (3.49%)
At close: Dec 5, 2025, 4:00 PM EST
4.760
+0.010 (0.21%)
After-hours: Dec 5, 2025, 4:10 PM EST
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M AUD with 538.86% growth. Radiopharm Theranostics had revenue of 10.07M in the half year ending June 30, 2025, with 417.19% growth.
Revenue (ttm)
12.51M AUD
Revenue Growth
+538.86%
P/S Ratio
4.95
Revenue / Employee
893,727 AUD
Employees
14
Market Cap
40.57M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |